|Printable version||E-mail this to a friend|
Strategic Vision for the European Railway Agency: the Engine for Change
Taking stock of the current situation, the European Railway Agency has analysed the political, economic, social, and technological environment of the European railway sector to formulate its vision for 2020:
As a respected European authority, the Agency will be the engine for change driving the Single European Railway Area.
Our ambition is not only to champion our new tasks as a European authority - issuing vehicle authorisation and safety certificates, and acting as system authority for ERTMS – which we are mandated to perform by the technical pillar of the 4th railway package.
We want to achieve 7 strategic objectives – from Europe becoming the world leader in railway safety to promoting rail transport to enhance its market share, to fostering the Agency’s reputation in the world.
Strategic Vision for the European Railway Agency (PDF)
Latest News from
EU scales up its assistance against cholera outbreak in Yemen26/06/2017 16:05:00
The EC is scaling up its response to an unprecedented cholera outbreak in Yemen with an additional €5m, bringing total EU support for efforts to tackle the disease to €8.8m.
Investments in EU Transport: Commission proposes €2.7bn for 152 projects26/06/2017 15:15:15
Recently the European Commission proposed to invest €2.7 billion in 152 key transport projects that support competitive, clean and connected mobility in Europe.
Europe’s shrinking middle class26/06/2017 14:25:00
In the follow blog piece, originally posted on Social Europe, Carlos Vacas-Soriano and Enrique Fernández-Macías look at evolution of household disposable real income levels over the period 2004-2013, and the broader phenomenon on Europe's shrinking middle class.
First ever guidance for stem cell therapies in animals published26/06/2017 13:10:00
Document gives advice on sterile manufacturing processes for veterinary stem cell medicines.
EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome26/06/2017 12:44:00
A review by the EMA has concluded that Symbioflor 2 and associated names can continue to be used for treatment of irritable bowel syndrome (IBS) in adults. However, the medicine should no longer be used more widely to treat so-called functional gastrointestinal disorders.